



## Exelixis Announces Webcasts of Investor Conference Presentations in December (Evercore presentation canceled)

November 26, 2019

– Presentations to be webcast on [www.exelixis.com](http://www.exelixis.com) –

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 26, 2019-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis' management team will provide an overview of the company at the following investor conferences in December:

- Evercore ISI 2<sup>nd</sup> Annual HealthCONx: Exelixis is scheduled to present at 8:45 AM EST / 5:45 AM PST on Tuesday, December 3, 2019 in Boston. **Update:** *Due to severe weather on the East Coast, which has significantly impacted flights into and out of Boston, Exelixis has canceled its participation at this conference.*
- Piper Jaffray 31<sup>st</sup> Annual Healthcare Conference: Exelixis is scheduled to present at 10:00 AM EST / 7:00 AM PST on Tuesday, December 3, 2019 in New York.

To access the webcast links, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

### About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX<sup>®</sup> (cabozantinib), COMETRIQ<sup>®</sup> (cabozantinib), COTELLIC<sup>®</sup> (cobimetinib) and MINNEBRO<sup>®</sup> (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit [www.exelixis.com](http://www.exelixis.com), follow [@ExelixisInc](https://twitter.com/ExelixisInc) on Twitter or like [Exelixis, Inc.](https://www.facebook.com/Exelixis.Inc) on Facebook.

*Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.*



View source version on businesswire.com: <https://www.businesswire.com/news/home/20191126005830/en/>

Source: Exelixis, Inc.

### Investors Contact:

Varant Shirvanian  
Sr. Investor Relations Manager  
Exelixis, Inc.  
650-837-7917  
[vshirvanian@exelixis.com](mailto:vshirvanian@exelixis.com)

### Media Contact:

Hal Mackins  
For Exelixis, Inc.  
415-994-0040  
[hal@torchcommunications.com](mailto:hal@torchcommunications.com)